https://www.selleckchem.com/pr....oducts/trastuzumab-e
The in vitro study revealed that treatment with vismodegib decreased BCC cell growth and migration; however, these effects were reversed by LV‑CD44s overexpression. The in vivo study revealed that BCC tumour growth was significantly increased in nude mice transplanted with cells stably infected with CD44s compared with nude mice transplanted with cells infected with a control vector. Our investigation demonstrated that lentivirus‑mediated CD44s expression may reverse the effects of vismodegib treatment on BCC.Coroso
Aimer
Commentaire
Partagez
